These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 19207096)

  • 1. Prulifloxacin: clinical studies of a broad-spectrum quinolone agent.
    Giannarini G; Tascini C; Selli C
    Future Microbiol; 2009 Feb; 4(1):13-24. PubMed ID: 19207096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prulifloxacin: a new antibacterial fluoroquinolone.
    Prats G; Rossi V; Salvatori E; Mirelis B
    Expert Rev Anti Infect Ther; 2006 Feb; 4(1):27-41. PubMed ID: 16441207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prulifloxacin.
    Keam SJ; Perry CM
    Drugs; 2004; 64(19):2221-34; discussion 2235-6. PubMed ID: 15456336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prulifloxacin versus levofloxacin in the treatment of respiratory and urinary tract infections: a multicentre, double-blind, randomized controlled clinical trial.
    Chen Y; Yang H; Lu G; Wu X; Huang W; Wu Y; Lv X; Wu G; Zhang G; Li Q; Sun Y
    Chemotherapy; 2012; 58(3):249-56. PubMed ID: 22890091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacologic characteristics of prulifloxacin.
    Matera MG
    Pulm Pharmacol Ther; 2006; 19 Suppl 1():20-9. PubMed ID: 16360331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic effect of the quinolone prodrug prulifloxacin against experimental urinary tract infections in mice.
    Tomii Y; Ozaki M; Matsuda M; Honmura T; Nishimura I; Yamaguchi R; Adachi T; Okawa Y; Nishino T
    Arzneimittelforschung; 1996 Dec; 46(12):1169-73. PubMed ID: 9006794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Penetration of orally administered prulifloxacin into human prostate tissue.
    Giberti C; Gallo F; Rosignoli MT; Ruggieri A; Barattè S; Picollo R; Dionisio P
    Clin Drug Investig; 2009; 29(1):27-34. PubMed ID: 19067472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prulifloxacin: a new fluoroquinolone for the treatment of acute exacerbation of chronic bronchitis.
    Cazzola M; Salvatori E; Dionisio P; Allegra L
    Pulm Pharmacol Ther; 2006; 19 Suppl 1():30-7. PubMed ID: 16359895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [In vitro activity of prulifloxacin, levofloxacin and ciprofloxacin against urinary pathogens].
    Noviello S; Ianniello F; Leone S; Esposito S
    Infez Med; 2006 Mar; 14(1):24-8. PubMed ID: 17405239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of prulifloxacin in the treatment of acute rhinosinusitis.
    Passali D; Crisanti A; Bellussi LM
    Infez Med; 2015 Dec; 23(4):301-6. PubMed ID: 26700078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prulifloxacin: a review focusing on its use beyond respiratory and urinary tract infections.
    Rafailidis PI; Polyzos KA; Sgouros K; Falagas ME
    Int J Antimicrob Agents; 2011 Apr; 37(4):283-90. PubMed ID: 21300527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interpretive criteria for disk diffusion susceptibility testing of ulifloxacin, the active metabolite of prulifloxacin.
    Montanari MP; Ferrante L; Tili E; Cochetti I; Rossi V; Varaldo PE
    J Chemother; 2005 Apr; 17(2):138-42. PubMed ID: 15920898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prulifloxacin versus levofloxacin in the treatment of severe COPD patients with acute exacerbations of chronic bronchitis.
    Blasi F; Schaberg T; Centanni S; Del Vecchio A; Rosignoli MT; Dionisio P
    Pulm Pharmacol Ther; 2013 Oct; 26(5):609-16. PubMed ID: 23538168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Penetration of prulifloxacin into gynaecological tissues after single and repeated oral administrations.
    Gorlero F; Lorenzi P; Rosignoli MT; Picollo R; Ruggieri A; Barattè S; Dionisio P
    Drugs R D; 2007; 8(6):373-81. PubMed ID: 17963428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delafloxacin for the treatment of respiratory and skin infections.
    Bassetti M; Della Siega P; Pecori D; Scarparo C; Righi E
    Expert Opin Investig Drugs; 2015 Mar; 24(3):433-42. PubMed ID: 25604710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
    Fritsche TR; Biedenbach DJ; Jones RN
    Antimicrob Agents Chemother; 2009 Mar; 53(3):1221-4. PubMed ID: 19114678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prulifloxacin versus ciprofloxacin in the treatment of adults with complicated urinary tract infections.
    Carmignani G; De Rose AF; Olivieri L; Salvatori E; Rosignoli MT; Dionisio P
    Urol Int; 2005; 74(4):326-31. PubMed ID: 15897698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Insights on the Pharmacokinetics of Ulifloxacin After Administration of Prulifloxacin in Patients with Mild, Moderate and Severe Renal Impairment.
    Tellone V; Coppola P; Ammendola M; Di Loreto G; Picollo R; Del Vecchio A; Comandini A; Garofolo F; Tongiani S
    Drugs R D; 2018 Sep; 18(3):237-245. PubMed ID: 30151791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tigecycline: a novel glycylcycline antibiotic.
    Zhanel GG; Karlowsky JA; Rubinstein E; Hoban DJ
    Expert Rev Anti Infect Ther; 2006 Feb; 4(1):9-25. PubMed ID: 16441206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ceftobiprole: a new cephalosporin for the treatment of skin and skin structure infections.
    Schirmer PL; Deresinski SC
    Expert Rev Anti Infect Ther; 2009 Sep; 7(7):777-91. PubMed ID: 19735220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.